Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Dao Kim-Hien 2. Date of Event Requiring Statement (Month/Day/Year) 09/18/2026 3. Issuer Name and Ticker or Trading Symbol Electra Therapeutics, Inc. [ETRA] (Last) (First) (Middle) C/O ELECTRA THERAPEUTICS, INC., 230 E GRAND AVENUE, SUITE S-100 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Medical Officer 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) SOUTH SAN FRANCISCO, CA 94080 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	(1)	08/08/2033	Common Stock	62,631	$4.4	D
Employee Stock Option (right to buy)	(2)	11/16/2033	Common Stock	23,634	$4.4	D
Employee Stock Option (right to buy)	(3)	05/08/2034	Common Stock	103,992	$5.05	D
Employee Stock Option (right to buy)	(4)	11/13/2034	Common Stock	47,269	$5.05	D
Employee Stock Option (right to buy)	(5)	02/12/2036	Common Stock	309,676	$4.96	D
Employee Stock Option (right to buy)	(6)	09/16/2036	Common Stock	155,979	$15	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Dao Kim-Hien C/O ELECTRA THERAPEUTICS, INC. 230 E GRAND AVENUE, SUITE S-100 SOUTH SAN FRANCISCO, CA 94080			Chief Medical Officer

Signatures

/s/ Jamie Kitano, Attorney-in-Fact		09/18/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	1/4th of the total shares subject to this option vested one year after April 3, 2023, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
(2)	1/4th of the total shares subject to this option vested one year after January 1, 2024, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
(3)	1/4th of the total shares subject to this option vested one year after May 16, 2024, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
(4)	1/4th of the total shares subject to this option vested one year after November 14, 2024, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
(5)	1/48th of the total shares subject to this option shall vest monthly commencing from February 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
(6)	1/48th of the total shares subject to this option shall vest monthly commencing from September 17, 2026.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.